Ocugen (NASDAQ:OCGN) presented top-line 12-month results from its Phase II ArMaDa clinical trial evaluating OCU410, a ...

The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural ...

These images are the results of a subretinal injection. Left is the image of the injection site in the retina, the green box indicates the plane in which the right image was taken. Right is the ...